Русский
Erenumab – an antimigraine drug: experience of use
DOI: https://dx.doi.org/10.18565/pharmateca.2024.1.164-168
Azimova Yu.E., Skorobogatykh K.V., Osipova V.V., Korobkova D.Z., Mamkhegov E.Z., Galanina A.S., Guziy E.A., Frolova A.V.
1) University Headache Clinic, Moscow, Russia; 2) Research Institute of General Pathology and Pathophysiology, Moscow, Russia; 3) Z.P. Solovyov Scientific and Practical Psychoneurological Center of the Moscow Healthcare Department, Moscow, Russia
Background. Studies of the effectiveness and safety of anti-CGRP therapy in routine clinical practice (Real World Studies), where patients with different forms of migraine, varying sensitivity to anti-migraine therapy, as well as concomitant and comorbid diseases are encountered, provide important information for neurologists.
Objective. Evaluation of the effectiveness, safety, and patterns of use of erenumab in the routine practice of a specialized headache center in the Russian Federation.
Methods. The open retrospective study included 126 patients followed-up at the University Headache Clinic (Moscow). The mean age of the patients was 40.3±9–10 years (19–67), women predominated (F – 111, M – 15).
Results. Before treatment, the frequency of days with migraine in the study group was 21.1±7.6 days; after 12 weeks, this figure was 10.2±8.3 (p<0.0001). Among patients with episodic migraine (EM), the frequency of days with migraine before therapy was 11.8±3.7, and after 12 weeks – 4.0 ± 3.3 (p < 0.0001). In the chronic migraine (CM) group, the frequency of days with migraine before treatment was 23.8±6.2, and after 12 weeks it was 11.9 ± 8.5 (p < 0.0001). The proportion of patients with ≥50% reduction in days with migraine after 12 weeks of therapy was 68.3% (n=86), with ≥75% reduction – 32.5% (n=41). The proportion of patients with a complete (100%) reduction in migraine days was 5.6% (n=7). In the EM group, the proportion of patients with ≥50% reduction was 86.2% (n=25), with ≥75% reduction – 41.4% (n=12). In the CM group, the proportion of patients with ≥50% reduction was 62.9% (n=61), with ≥75% reduction – 29.9% (n=41). It should be noted that erenumab was well tolerated at a dose of 70 mg once a month: one patient developed a tendency to constipation, and one patient experienced an increase in blood pressure.
Conclusion. Thus, erenumab is an effective and safe drug for the prevention of migraine in everyday practice and can be recommended for patients with various forms of migraine.
Objective. Evaluation of the effectiveness, safety, and patterns of use of erenumab in the routine practice of a specialized headache center in the Russian Federation.
Methods. The open retrospective study included 126 patients followed-up at the University Headache Clinic (Moscow). The mean age of the patients was 40.3±9–10 years (19–67), women predominated (F – 111, M – 15).
Results. Before treatment, the frequency of days with migraine in the study group was 21.1±7.6 days; after 12 weeks, this figure was 10.2±8.3 (p<0.0001). Among patients with episodic migraine (EM), the frequency of days with migraine before therapy was 11.8±3.7, and after 12 weeks – 4.0 ± 3.3 (p < 0.0001). In the chronic migraine (CM) group, the frequency of days with migraine before treatment was 23.8±6.2, and after 12 weeks it was 11.9 ± 8.5 (p < 0.0001). The proportion of patients with ≥50% reduction in days with migraine after 12 weeks of therapy was 68.3% (n=86), with ≥75% reduction – 32.5% (n=41). The proportion of patients with a complete (100%) reduction in migraine days was 5.6% (n=7). In the EM group, the proportion of patients with ≥50% reduction was 86.2% (n=25), with ≥75% reduction – 41.4% (n=12). In the CM group, the proportion of patients with ≥50% reduction was 62.9% (n=61), with ≥75% reduction – 29.9% (n=41). It should be noted that erenumab was well tolerated at a dose of 70 mg once a month: one patient developed a tendency to constipation, and one patient experienced an increase in blood pressure.
Conclusion. Thus, erenumab is an effective and safe drug for the prevention of migraine in everyday practice and can be recommended for patients with various forms of migraine.
About the Autors
Corresponding author: Yulia E. Azimova, Dr. Sci. (Med.), neurologist, University Headache Clinic; Leading Researcher at the Laboratory of Fundamental and Applied Problems of Pain, Research Institute of General Pathology and Pathophysiology, Moscow, Russia; azimova.j@mail.ru
Similar Articles
